• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel

Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel

July 3, 2012
CenterWatch Staff

Swiss research-driven specialty biopharmaceutical group Ferring Pharmaceuticals and Swedish biotech Albireo have signed a license agreement under which Ferring has rights to develop and commercialize elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

The agreement gives Ferring rights to market elobixibat globally with the exception of Japan and a small number of Asian markets. In consideration of the rights, Ferring will pay Albireo a significant upfront undisclosed licensing fee, milestones and tiered double-digit royalties. Ferring will also be responsible for development costs in its territory.

The agreement is one of the biggest investments made by Ferring for licensing rights of a product. Ferring believes that the novel therapy elobixibat, which is targeting a currently under-served, but large patient population, will significantly strengthen its gastroenterology portfolio. Elobixibat is due to enter phase III trials for the CIC indication and phase IIB trials for the IBS-C indication shortly.

"Elobixibat perfectly complements our gastroenterology portfolio, which includes Pentasa for IBD and Picoprep for bowel cleansing. We also have several promising products in our pipeline within gastroenterology," said Michel Pettigrew, president of the executive board and COO at Ferring. "It fits well with our company philosophy of ‘People Come First’—in particular the patient, as it addresses a problem that affects from 15% up to almost a third of the population, but that has seen little progress in treatment options over the years."

Jan Mattsson, executive director of the board and COO of Albireo, added, "We are excited to enter into this agreement and look forward to collaborating with Ferring to bring this novel therapy to patients around the world suffering from CIC or IBS-C. Ferring has a long and strong track record in gastroenterology and we believe will be an ideal partner for Albireo and elobixibat in this territory."

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing